Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design

Medicinal Chemistry

Volumn 5, Issue 3, 2009, Pages 242-249

  Gong, Ke ^a   Li, Lin ^a   Wang, Jing Fang ^b   Cheng, Feng ^c   Wei, Dong Qing ^a,d   Chou, Kuo Chen ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c UNIVERSITY OF VIRGINIA   (United States)

^d GORDON LIFE SCIENCE INSTITUTE   (United States)

Author keywords

Active site; AG7088; Avian influenza; Bird flu; Drug design; H5N1; Neuraminidase; Structural bioinformatics

Indexed keywords

LIGAND; OSELTAMIVIR; RUPINTRIVIR; SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR;

ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; HYDROGEN BOND; INFLUENZA VIRUS A H5N1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SIMULATION; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; PROTEIN BINDING;

EID: 67651146680     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609788185936     Document Type: Article

References (61)

1. Horimoto, T.; Kawaoka, Y. Pandemic threat posed by avian influenza A viruses. Clin. Mircobiol. Rev., 2001, 14, 129-149.
2. Trampuz, A.; Prabhu, R. M.; Smith, T. F.; Baddour, L. M. Avian influenza: a new pandemic threat? Mayo Clin. Proc., 2004, 79, 523-530.
3. Colman, P. M.; Tulip, W. R.; Varghese, J. N.; Tulloch, P. A.; Baker, A. T.; Laver, W. G.; Air, G. M.; Webster, R. G. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R Soc. Lond. B Biol. Sci., 1989, 323, 511-518.
4. Smith, B. J.; Colman, P. M.; von Itzstein, M.; Danylec, B.; Varghese, J. N. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci., 2001, 10, 689-696.
5. Oxford, J. S.; Novelli, P.; Sefton, A.; Lambkin, R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir. Chem. Chemoth., 2002, 13, 205-217.
6. Liu, C.; Eichelberger, M. C.; Compans, R. W.; Air, G. M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol., 1995, 69, 1099-1106.
7. McKimm-Breschkin, J. L. Resistance of influenza viruses to neuraminidase inhibitors, a review. Antivir. Res., 2000, 47, 1-17.
8. Hayden, F. G. Perspectivies on antriviral use during pandemic influenza. Phios. Trans. R Soc. Lond. B Biol. Sci., 2001, 356, 1877-1884.
9. Ward, P.; Small, I.; Smith, J.; Suter, P.; Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemoth., 2005, 55 (Suppl 1), 5-21.
10. Mishin, V. P.; Hayden, F. G.; Gubareva, L. V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemoth., 2005, 49, 4515-4520.
11. Le, Q. M.; Kiso, M.; Someya, K.; Sakai, Y. T.; Nguyen, T. H.; Nguyen, K. H.; Pham, N. D.; Ngyen, H. H.; Yamada, S.; Muramoto, Y.; Kawaoka, Y. Avain flu: isolation of drug-resistant H5N1 virus. Nature, 2005, 437, 1108.
12. de Jong, M. D.; Tran, T. T.; Truong, H. K.; Vo, M. H.; Smith, G. J.; Nguyen, V. C.; Bach, V. C.; Phan, T. Q.; Do, Q. H.; Guan, Y.; Peiris, J. S.; Tran, T. H.; Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. New Engl. J. Med., 2005, 353, 2667-2672.
13. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem., 2004, 11, 2105-2134.
14. Lubec, G.; Afjehi-Sadat, L.; Yang, J. W.; John, J. P. Searching for hypothetical proteins: theory and practice based upon original data and literature. Prog. Neurobiol., 2005, 77, 90-127.
15. Chou, K. C. Review: Prediction of HIV protease cleavage sites in proteins. Anal. Biochem., 1996, 233, 1-14.
16. Gonzalez-Diaz, H.; Gonzalez-Diaz, Y.; Santana, L.; Ubeira, F. M.; Uriarte, E. Proteomics, networks, and connectivity indices. Proteomics, 2008, 8, 750-778.
17. Shen, H. B.; Chou, K. C. HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins. Anal. Biochem., 2008, 375, 388-390.
18. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design aganist SARS. Biochem. Biophys. Res. Commun., 2003, 308, 148-151. (Erratum: ibid., 2003, 310, 675)
19. Sirois, S.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem. Inf. Comput. Sci., 2004, 44, 1111-1122.
20. Wei, D. Q.; Sirois, S.; Du, Q. S.; Arias, H. R.; Chou, K. C. Theoretical studies of Alzheimer's disease drug candidate [(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives. Biochem. Biophys. Res. Commun., 2005, 338, 1059-1064.
21. Du, Q. S.; Wang, S.; Wei, D. Q.; Sirois, S.; Chou, K. C. Molecular modeling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biochem., 2005, 337, 262-270.
22. Du, Q. S.; Wang, S. Q.; Jiang, Z. Q.; Gao, W. N.; Li, Y. D.; Wei, D. Q.; Chou, K. C. Application of bioinforamtics in search for cleavable peptides of SARS-CoV Mpro and chemical modification of octapeptides. Med. Chem., 2005, 1, 209-213.
23. Wei, D. Q.; Zhang, R.; Du, Q. S.; Gao, W. N.; Li, Y.; Gao, H.; Wang, S. Q.; Zhang, X.; Li, A. X.; Sirois, S.; Chou, K. C. Anti-SARS drug screening by molecular docking. Amino Acids, 2006, 31, 73-80.
24. Wei, D. Q.; Du, Q. S.; Sun, H.; Chou, K. C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun., 2006, 344, 1048-1055.
25. Chou, K. C.; Wei, D. Q.; Du, Q. S.; Sirois, S.; Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13, 3263-3270.
26. Zhang R.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Molecular modeling studies of peptide drug candidates against SARS. Med. Chem., 2006, 2, 309-314.
27. Gan, Y. R.; Huang, H.; Huang, Y. D.; Rao, C. M.; Zhao, Y.; Liu, J. S.; Wu, L.; Wei, D. Q. Synthesis and activity assess of an octapeptide inhibitor designed for SARS coronavirus main proteinase. Peptides, 2006, 27, 622-625.
28. Wang, S. Q.; Du, Q. S.; Chou, K. C. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem. Biophys. Res. Commun., 2007, 354, 634-640.
29. Wang, J. F.; Wei, D. Q.; Li, L.; Zheng, S. Y.; Li, Y. X.; Chou, K. C. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem. Biophys. Res. Commun., 2007, 355, 513-519. (Corrigendum: ibid, 2007, 357, 330)
30. Wang, J. F.; Wei, D. Q.; Lin, Y.; Wang, Y. H.; Du, H. L.; Li, Y. X.; Chou, K. C. Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP. Biochem. Biophys. Res. Commun., 2007, 359, 323-329.
31. Wang, S. Q.; Du, Q. S.; Zhao, K.; Li, A. X.; Wei, D. Q.; Chou, K. C. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids, 2007, 33, 129-135.
32. Du, Q. S.; Sun, H.; Chou, K. C. Inhibitor design for SARS coronavirus main protease based on "distorted key theory". Med. Chem., 2007, 3, 1-6.
33. Du, Q. S.; Wang, S. Q.; Chou, K. C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem. Biophys. Res. Commun., 2007, 362, 525-531.
34. Li, Y.; Wei, D. Q.; Gao, W. N.; Gao, H.; Liu, B. N.; Huang, C. J.; Xu, W. R.; Liu, D. K.; Chen, H. F.; Chou, K. C. Computational approach to drug design for oxazolidinones as antibacterial agents. Med. Chem., 2007, 3, 576-582.
35. Li, L.; Wei. D. Q.; Wang, J. F.; Chou, K. C. Computational studies of the binding mechanism of calmodulin with chrysin. Biochem. Biophys. Res. Commun., 2007, 358, 1102-1107.
36. Zheng, H.; Wei, D. Q.; Zhang, R.; Wang, C.; Wei, H.; Chou, K. C. Screening for new agonists against Alzheimer's disease. Med. Chem., 2007, 3, 488-493.
37. Wei, H.; Zhang, R.; Wang, C.; Zhang, H.; Chou, K. C.; Wei, D. Q. Molecular insights of SAH enzyme catalysis and their implication for inhibitor design. J. Theor. Biol., 2007, 244, 692-702.
38. Gao, W. N.; Wei, D. Q.; Li, Y.; Gao, H.; Xu, W. R.; Li, A. X.; Chou, K. C. Agaritine and its derivatives are potential inhibitors against HIV proteases. Med. Chem., 2007, 3, 221-226.
39. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des., 1996, 10, 293-304.
40. Chou, K. C.; Carlacci, L. Simulated annealing approach to the study of protein structures. Protein Eng., 1991, 4, 661-667.
41. Buck, M.; Bouguet-Bonnet, S.; Pastor, R. W.; MacKerell, A. D. Importance of the CMAP correction to the CHARMM22 protein force field: dynamics of hen lysozyme. Biophys. J., 2006, 90, 36-38.
42. Chou, K. C. Insights from modeling the tertiary structure of BACE2. J. Proteome Res., 2004, 3, 1069-1072.
43. Chou, K. C. Insights from modeling the 3D structure of the extracellular domain of alpha 7 nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun., 2004, 319, 433-438.
44. Chou, K. C. Molecular therapeutic target for type-2 diabetes. J. Proteome Res., 2004, 3, 1284-1288.
45. Chou, K. C. Modeling the tertiary structure of human cathepsin-E. Biochem. Biophys. Res. Commun., 2005, 331, 56-60.
46. Chou, K. C. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J. Proteome Res., 2005, 4, 1681-1686.
47. Chou, K. C.; Watenpaugh, K. D.; Heinrikson, R. L. A model of the complex domain of neuronal Cdk5 activator. Biochem. Biophys. Res. Commun., 1999, 259, 420-428.
48. Zhang, J.; Luan, C. H.; Chou, K. C.; Johnson, G. V. W. Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. Proteins., 2002, 48, 447-453.
49. Allen, M. P.; Wilson, M. R. Computer simulation of liquid crystals. J. Comput. Aided Mol. Des., 1989, 3, 335-353.
50. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blcakburn, G. M.; Hay, A. J.; Gamblin, S. J.; Skehel, J. J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443, 45-49.
51. Chou, K. C.; Shen, H. B. Review: Recent progresses in protein subcellular location prediction. Anal. Biochem., 2007, 370, 1-16.
52. Hagmann, M. Colleagues say "Amen" to this year's (Nobel Prizes) choice. Science, 1999, 286, 666.
53. Chou, K. C. Review: Prediction of protein signal sequences. Curr. Protein Pept. Sci., 2002, 3, 615-622.
54. Chou, K. C.; Shen, H. B. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat. Protoc., 2008, 3, 153-162.
55. Shen, H. B.; Chou, K. C. Virus-PLoc: A fusion classifier for predicting the subcellular localization of viral proteins within host and virus-infected cells. Biopolymers, 2007, 85, 233-240.
56. Chou, K. C.; Shen, H. B. MemType-2L: A web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem. Biophys. Res. Commun., 2007, 360, 339-345.
57. Shen, H. B.; Chou, K. C. EzyPred: A top-down approach for predicting enzyme functional classes and subclasses. Biochem. Biophys. Res. Commun., 2007, 364, 53-59.
58. Chou, K. C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Commun., 2007, 357, 633-640.
59. Shen, H. B.; Chou, K. C. Signal-3L: a 3-layer approach for predicting signal peptides. Biochem. Biophys. Res. Commun., 2007, 363, 297-303.
60. Borman, S. Flu virus proton channel analyzed: structures of key surface protein suggest different drug mechanisms. Chem. Eng. News, 2008, 86, 53-54.
61. Schnell, J. R.; Chou, J. J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008, 451, 591-595.